Corona 19 vaccine approved for clinical trial. (Photo = Yonhap News/Material photo)-As the government’s securing of the Corona 19 vaccine is slow, interest is shifting to the corona treatment being developed in Korea.
Currently, there are 29 clinical trials in Korea for the treatment of Corona 19, of which eight have ended and 21 are in progress. Most of the completed clinical trials are’remdesivir’, which was developed as an Ebola treatment. When Remdesivir was in the limelight abroad in the early stages of the Corona 19 crisis, clinical trials were underway in Korea, but it is revealed that there is no’special effect’ that can alleviate the Corona 19 incident at once.
Of the 21 cases in progress, 2 are in Phase 3, 10 are in Phase 2, and the rest are in Phase 1.
The two phase 3 cases are Celltrion’s new drug’CT-P59′ and’LY3009104′ (ingredient name varicitinib) developed by the multinational pharmaceutical company Eli Lilly as an autoimmune treatment.
Phase 2 treatments include Green Cross’s’GC5131′, Daewoong Pharmaceutical’s’Hoistar’, Dongwha Pharm’s’DW2008S’, Bukwang Pharmaceutical’s’Levovir’, Shinpoong Pharmaceutical’s’Pyramax’, and NGChem Life Science’s’EC-18′ Immune. Med’hzVSF-v13′, Chong Kun Dang’s’CKD-314′, Crystal Genomics”CG-CAM20′, Korea MSD’s’MK-4482′, etc.
Among them, Celltrion’s’CT-P59′ and Green Cross’s’GC5131′ are treatments that use antibodies. In the case of Celltrion, a neutralizing antibody that neutralizes the Corona 19 virus is extracted and mass-produced through cell culture. The Green Cross treatment is a plasma fractionation method made by filtering and concentrating only neutralizing antibodies remaining in the plasma of a cure for Corona 19. Both use antibodies, but the difference is whether they are mass-produced in factories or produced in the human body. In the case of factory mass production, huge facility costs are required in trillions, and the plasma fractionation method has the disadvantage that a cure must be continuously generated.
The rest of the treatment is a’drug re-creation’ method that applies drugs developed as treatments for other viral diseases to Corona 19, using mechanisms such as interfering with enzymes or RNA replication related to the human infection process of the Corona 19 virus.
Pharmaceutical companies in phases 2 and 3 plan to apply for’conditional approval’ to the Ministry of Food and Drug Safety early next year as soon as clinical results are available.
However, it remains to be seen whether these treatments will become a’game changer’ that can calm the Corona 19 situation in one shot. As’remdesivir’ and’chloroquine’, which were announced to have excellent therapeutic effects, have recently been controversial in efficacy, other treatments have not yet produced satisfactory clinical results during the treatment period, virus reduction rate, or negative period. Because there is.
–
